Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir - Shinada, Kanako; Sato, Takashi; Moriyama, Saya; Adachi, Yu; Shinoda, Masahiro; Ota, Shinichiro; Morikawa, Miwa; Mineshita, Masamichi; Matsumura, Takayuki; Takahashi, Yoshimasa; Shinkai, Masaharu (Viruses, 2022)
Keywords: Age; Amides - therapeutic use; Antibodies; Antibodies, Neutralizing - metabolism; Antibodies, Viral; Antiviral drugs; Body mass index; Clinical trials; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Disease; favipiravir; FDA approval; Gender; Hospitals; Humans; Immunoglobulin G; Infections; Influenza; neutralization breadth index; Neutralization Tests; neutralizing antibody; neutralizing potency index; Nucleoside analogs; Patients; Plasma; Pneumonia; Polymerase chain reaction; Pyrazines - therapeutic use; RNA polymerase; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - metabolism; Spike protein; United States--US; Japan; COVID-19; neutralizing antibody; SARS-CoV-2; neutralization breadth index; neutralizing potency index; favipiravir